Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 4, keine Gesamtzahl für „increases“
Suchtreffer
Begriffe & Kennungen
Forsteo · 4.8 · FORSTEO increases serum uric acid concentrations. In clinical trials, 2.8 % of FORSTEO patients had serum uric
Eintrag öffnenGenvoya · 4.8 · Changes in lipid laboratory tests In studies in treatment-naïve patients, increases from baseline were observe
Eintrag öffnenGenvoya · 4.8 · Changes in serum creatinine Cobicistat increases serum creatinine due to inhibition of tubular secretion of cr
Eintrag öffnenGilenya · 4.8 · Mild isolated bilirubin increases have been noted in paediatric patients on fingolimod.
Eintrag öffnenGlivec · 4.5 · Imatinib increases the mean Cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, indi
Eintrag öffnenHemgenix · 4.8 · Laboratory Parameter Increasesa Number of patients (%) N = 57f ALT increases > ULNb 23 (40.4%) c > ULN – 3.0 x
Eintrag öffnenHepcludex · 4.8 · Eosinophilia Increases in eosinophil counts were commonly observed in patients receiving bulevirtide treatment
Eintrag öffnenIfirmacombi · 4.5 · Lithium: Reversible increases in serum lithium concentrations and toxicity have been reported during concomita
Eintrag öffnenIfirmasta (previously Irbesartan Krka) · 4.5 · Lithium: Rreversible increases in serum lithium concentrations and toxicity have been reported during concomit
Eintrag öffnenIfirmasta (previously Irbesartan Krka) · 4.8 · Common: significant increases in plasma creatine kinase were commonly observed (1.7%) in irbesartan treated su
Eintrag öffnenIlaris · 4.8 · ALT/AST Mean and median increases in alanine transaminase (ALT) of 3.0 U/l and 2.0 U/l, respectively, and in a
Eintrag öffnenIlaris · 4.8 · Uric acid Increases in uric acid level (0.7 mg/dl at 12 weeks and 0.5 mg/dl at 24 weeks) were observed after c
Eintrag öffnenImaavy · 4.8 · In adult and adolescent patients with gMG who received nipocalimab, increases in lipids were observed in most
Eintrag öffnenInaqovi · 4.5 · Cedazuridine is an inhibitor of CDA and thereby increases the exposure of decitabine following oral administra
Eintrag öffnenInhixa · 4.8 · Hepatobiliary disorders Very common: Hepatic enzyme increases (mainly transaminases > 3 times the upper limit
Eintrag öffnenInhixa · 4.8 · Hepatobiliary disorders Very common: Hepatic enzyme increases (mainly transaminases > 3 times the upper limit
Eintrag öffnenInhixa · 4.8 · Hepatobiliary disorders Very common: Hepatic enzyme increases (mainly transaminases > 3 times the upper limit
Eintrag öffnenInhixa · 4.8 · Hepatobiliary disorders Very common: Hepatic enzyme increases (mainly transaminases > 3 times the upper limit
Eintrag öffnenInhixa · 4.8 · Hepatobiliary disorders Very common: Hepatic enzyme increases (mainly transaminases > 3 times the upper limit
Eintrag öffnenInhixa · 4.8 · Hepatobiliary disorders Very common: Hepatic enzyme increases (mainly transaminases > 3 times the upper limit
Eintrag öffnen